Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 2/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10025158 | 0.91 | NPC1 (0.60) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| SCHEMBL4671332 | 0.90 | MEN1 (0.66) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL16432330 | 0.88 | MEN1 (0.69) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| SCHEMBL4671330 | 0.88 | ALDH1A1 (0.55) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| Bromide SCHEMBL10966281 | 0.88 | MEN1 (0.64) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| SCHEMBL2987582 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| SCHEMBL10965626 | 0.87 | MGLL (0.60) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| SCHEMBL2987583 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| SCHEMBL2987579 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MGLLHSD11B1MEN1KMT2A | |
| SCHEMBL14067799 | 0.86 | NPSR1 (0.49) | ALDH1A1MGLLHSD11B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-8772500-B2 | TRPV3 modulators | ABBVIE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013062966-A2 | NOVEL TRPV3 MODULATORS | ABBVIE INC. (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273738-B2 | Imidazole derivatives | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2090570-B1 | IMIDAZOLE DERIVATIVE | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-8044042-B2 | Thienotriazolodiazepine compound and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-25 | — | — | US | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-02-18 | — | — | US | disclosed |
| EP-2090570-A1 | IMIDAZOLE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-08-19 | — | — | EP | disclosed |
| EP-1887008-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND A MEDICINAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-02-13 | — | — | EP | disclosed |
| EP-1492537-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082294-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131036-A1 | NOVEL TRPV3 MODULATORS | TRPV3, TRPV4, TRPV5 | ALDH1A1 2763/4885MGLL 4122/4885HSD11B1 2884/4885 |
| US-20230151037-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | ALDH1A1 1768/4885MGLL 315/4885HSD11B1 1033/4885 |
| US-20120289502-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | ALDH1A1 2997/4885MGLL 385/4885HSD11B1 1158/4885 |
| US-20100041643-A1 | THIENOTRIAZOLODIAZEPINE COMPOUND AND MEDICINAL USE THEREOF | ICOS, CD4, CD2 | ALDH1A1 2055/4885MGLL 4371/4885HSD11B1 2761/4885 |
| US-20100152178-A1 | IMIDAZOLE DERIVATIVES | CNR1, CNR2, ARRB1 | ALDH1A1 2997/4885MGLL 385/4885HSD11B1 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.